{"pmid":32441786,"title":"Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.","text":["Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.","The use of corticosteroids has been controversial in viral pneumonia. In most cases, application of methylprednisolone in severe and critical viral pneumonia patients can quickly alleviate the symptoms of dyspnea and prevent disease progression. However, some scholars have confirmed that corticosteroids delayed the body's clearance of the virus. In our retrospective non-randomised study, 34 patients under 50 years old and diagnosed with coronavirus disease 2019 (COVID-19) were included, according to given methylprednisolone treatment (n = 18) or not (n = 16), they were separated into 2 groups. By comparing the clinical data we concluded that corticosteroids therapy can effectively release COVID-19 symptoms such as persistent fever and difficult breathing, improve oxygenation and prevent disease progression. However, it can prolong the negative conversion of nucleic acids. This article is protected by copyright. All rights reserved.","J Med Virol","Gong, Yuan","Guan, Li","Jin, Zhu","Chen, Shixiong","Xiang, Guangming","Gao, Baoan","32441786"],"abstract":["The use of corticosteroids has been controversial in viral pneumonia. In most cases, application of methylprednisolone in severe and critical viral pneumonia patients can quickly alleviate the symptoms of dyspnea and prevent disease progression. However, some scholars have confirmed that corticosteroids delayed the body's clearance of the virus. In our retrospective non-randomised study, 34 patients under 50 years old and diagnosed with coronavirus disease 2019 (COVID-19) were included, according to given methylprednisolone treatment (n = 18) or not (n = 16), they were separated into 2 groups. By comparing the clinical data we concluded that corticosteroids therapy can effectively release COVID-19 symptoms such as persistent fever and difficult breathing, improve oxygenation and prevent disease progression. However, it can prolong the negative conversion of nucleic acids. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Gong, Yuan","Guan, Li","Jin, Zhu","Chen, Shixiong","Xiang, Guangming","Gao, Baoan"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441786","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26052","keywords":["covid-19","ct image lesion","methylprednisolone","treatment","virus nucleic acid"],"e_drugs":["Methylprednisolone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667523504800530434,"score":9.490897,"similar":[{"pmid":32391369,"pmcid":"PMC7193030","title":"Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature.","text":["Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature.","The aim was to investigate the effectiveness of glucocorticoid therapy in patients with COVID-19. A systematic search of the literature across nine databases was conducted from inception until 15th March 2020, following the PRISMA guidelines. Patients with a validated diagnosis of COVID-19 and using corticosteroids were included, considering all health outcomes. Four studies with 542 Chinese participants were included. Two studies reported negative findings regarding the use of corticosteroids in patients with COVID-19, i.e., corticosteroids had a detrimental impact on clinical outcomes. One study reported no significant association between the use of corticosteroids and clinical outcomes. However, one study, on 201 participants with different stages of pneumonia due to COVID-19, found that in more severe forms, the administration of methylprednisolone significantly reduced the risk of death by 62%. The literature to date does not fully support the routine use of corticosteroids in COVID-19, but some findings suggest that methylprednisolone could lower mortality rate in more severe forms of the condition.","Front Med (Lausanne)","Veronese, Nicola","Demurtas, Jacopo","Yang, Lin","Tonelli, Roberto","Barbagallo, Mario","Lopalco, Pierluigi","Lagolio, Erik","Celotto, Stefano","Pizzol, Damiano","Zou, Liye","Tully, Mark A","Ilie, Petre Cristian","Trott, Mike","Lopez-Sanchez, Guillermo F","Smith, Lee","32391369"],"abstract":["The aim was to investigate the effectiveness of glucocorticoid therapy in patients with COVID-19. A systematic search of the literature across nine databases was conducted from inception until 15th March 2020, following the PRISMA guidelines. Patients with a validated diagnosis of COVID-19 and using corticosteroids were included, considering all health outcomes. Four studies with 542 Chinese participants were included. Two studies reported negative findings regarding the use of corticosteroids in patients with COVID-19, i.e., corticosteroids had a detrimental impact on clinical outcomes. One study reported no significant association between the use of corticosteroids and clinical outcomes. However, one study, on 201 participants with different stages of pneumonia due to COVID-19, found that in more severe forms, the administration of methylprednisolone significantly reduced the risk of death by 62%. The literature to date does not fully support the routine use of corticosteroids in COVID-19, but some findings suggest that methylprednisolone could lower mortality rate in more severe forms of the condition."],"journal":"Front Med (Lausanne)","authors":["Veronese, Nicola","Demurtas, Jacopo","Yang, Lin","Tonelli, Roberto","Barbagallo, Mario","Lopalco, Pierluigi","Lagolio, Erik","Celotto, Stefano","Pizzol, Damiano","Zou, Liye","Tully, Mark A","Ilie, Petre Cristian","Trott, Mike","Lopez-Sanchez, Guillermo F","Smith, Lee"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391369","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3389/fmed.2020.00170","keywords":["ards","covid-19","sars-cov-2","coronavirus","corticosteroids","methylprednisolone","pneumonia"],"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Methylprednisolone"],"topics":["Treatment"],"weight":1,"_version_":1666528580116414464,"score":237.3958},{"pmid":32479759,"pmcid":"PMC7256545","title":"Successful use of methylprednisolone for treating severe COVID-19.","text":["Successful use of methylprednisolone for treating severe COVID-19.","Timely and appropriate application of methylprednisolone in severe and critical COVID-19 patients could effectively avoid invasive mechanical ventilation and reduce the mortality.","J Allergy Clin Immunol","Liu, Jing","Zheng, Xiaobin","Huang, Yiying","Shan, Hong","Huang, Jin","32479759"],"abstract":["Timely and appropriate application of methylprednisolone in severe and critical COVID-19 patients could effectively avoid invasive mechanical ventilation and reduce the mortality."],"journal":"J Allergy Clin Immunol","authors":["Liu, Jing","Zheng, Xiaobin","Huang, Yiying","Shan, Hong","Huang, Jin"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479759","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jaci.2020.05.021","keywords":["igg","methylprednisolone","prognosis","severe covid-19","treatment"],"e_drugs":["Methylprednisolone"],"topics":["Treatment"],"weight":1,"_version_":1668532089506496512,"score":210.86041},{"pmid":32270882,"title":"False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence.","text":["False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence.","A novel coronavirus (COVID-19) pandemic cause by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) threatens the world. We read with interest the recent report by Li et al. that included 610 patients with Coronavirus Disease 2019 (COVID-19). They reported a high false-negative rate of real-time reverse transcription polymerase chain reaction (RT-PCR) results for SARS-CoV-2 detection. In addition, recent report regarding SARS-CoV-2 \"turn positive\" in recovered cases with COVID-19 were published. Here, we studied the characteristics of nucleic acid conversion for SARS-CoV-2 from 70 COVID-19 patients. We found that 15 (21.4%) patients experienced a \"turn positive\" of nucleic acid detection by RT-PCR test for SARS-CoV-2 after two consecutive negative results, which may be related to the false negative of RT-PCR test and prolonged nucleic acid conversion This article is protected by copyright. All rights reserved.","J Med Virol","Xiao, Ai Tang","Tong, Yi Xin","Zhang, Sheng","32270882"],"abstract":["A novel coronavirus (COVID-19) pandemic cause by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) threatens the world. We read with interest the recent report by Li et al. that included 610 patients with Coronavirus Disease 2019 (COVID-19). They reported a high false-negative rate of real-time reverse transcription polymerase chain reaction (RT-PCR) results for SARS-CoV-2 detection. In addition, recent report regarding SARS-CoV-2 \"turn positive\" in recovered cases with COVID-19 were published. Here, we studied the characteristics of nucleic acid conversion for SARS-CoV-2 from 70 COVID-19 patients. We found that 15 (21.4%) patients experienced a \"turn positive\" of nucleic acid detection by RT-PCR test for SARS-CoV-2 after two consecutive negative results, which may be related to the false negative of RT-PCR test and prolonged nucleic acid conversion This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Xiao, Ai Tang","Tong, Yi Xin","Zhang, Sheng"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32270882","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/jmv.25855","keywords":["coronavirus < virus classification","sars coronavirus < virus classification","shedding < pathogenesis"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491747041283,"score":188.44514},{"pmid":32335406,"pmcid":"PMC7175870","title":"Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19.","text":["Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19.","Factors associated with negative conversion of SARS-CoV-2 RNA in hospitalized patients have not yet been systematically determined. We conducted a retrospective cohort study of COVID-19 patients in Qingdao, China. Both univariate and multivariate analysis were performed to identify independent factors for time to viral RNA negative conversion. Data on patients with re-detectable viral RNA after showing negative on RT-PCR test (intermittent negative status) were also analyzed. A total of 59 patients confirmed with COVID-19 were included in this study, with a median duration of 1 (interquartile range, IQR: 0-2) day from symptom onset to hospital admission. Median communicable period (from first day of positive nucleic acid test to first day of consecutive negative results) was 14 (IQR: 10-18) days, and 7 (IQR: 6-10) days for 10 patients with intermittent negative results. Age older than 45 years (hazard ratio, HR: 0.378; 95% confidence interval, CI: 0.205-0.698) and chest tightness (HR: 0.290; 95%CI: 0.091-0.919) were factors indecently affecting negative conversion of SARS-CoV-2 RNA. Headache (odds ratio: 7.553; 95%CI: 1.011-28.253) was significantly associated with intermittent negative status, with a predicted probability of 60%. Older age and chest tightness were independently associated with delayed clearance of SARS-CoV-2 RNA in hospitalized patients. These predictors would provide a new perspective on early identification of patients with prolonged viral shedding and facilitate optimal isolation protocols and treatment strategies.","Sci Total Environ","Hu, Xiaowen","Xing, Yuhan","Jia, Jing","Ni, Wei","Liang, Jiwei","Zhao, Dan","Song, Xin","Gao, Ruqin","Jiang, Fachun","32335406"],"abstract":["Factors associated with negative conversion of SARS-CoV-2 RNA in hospitalized patients have not yet been systematically determined. We conducted a retrospective cohort study of COVID-19 patients in Qingdao, China. Both univariate and multivariate analysis were performed to identify independent factors for time to viral RNA negative conversion. Data on patients with re-detectable viral RNA after showing negative on RT-PCR test (intermittent negative status) were also analyzed. A total of 59 patients confirmed with COVID-19 were included in this study, with a median duration of 1 (interquartile range, IQR: 0-2) day from symptom onset to hospital admission. Median communicable period (from first day of positive nucleic acid test to first day of consecutive negative results) was 14 (IQR: 10-18) days, and 7 (IQR: 6-10) days for 10 patients with intermittent negative results. Age older than 45 years (hazard ratio, HR: 0.378; 95% confidence interval, CI: 0.205-0.698) and chest tightness (HR: 0.290; 95%CI: 0.091-0.919) were factors indecently affecting negative conversion of SARS-CoV-2 RNA. Headache (odds ratio: 7.553; 95%CI: 1.011-28.253) was significantly associated with intermittent negative status, with a predicted probability of 60%. Older age and chest tightness were independently associated with delayed clearance of SARS-CoV-2 RNA in hospitalized patients. These predictors would provide a new perspective on early identification of patients with prolonged viral shedding and facilitate optimal isolation protocols and treatment strategies."],"journal":"Sci Total Environ","authors":["Hu, Xiaowen","Xing, Yuhan","Jia, Jing","Ni, Wei","Liang, Jiwei","Zhao, Dan","Song, Xin","Gao, Ruqin","Jiang, Fachun"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335406","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.scitotenv.2020.138812","keywords":["coronavirus disease 2019 (covid-19)","hazard ratio","negative conversion","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"],"locations":["Qingdao","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138494121017346,"score":181.26726},{"pmid":32391668,"title":"[Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids].","text":["[Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids].","OBJECTIVE: To investigate the effect of corticosteroids therapy on the inflammatory response in a critically ill coronavirus disease 2019 (COVID-19) patient. METHODS: A 55-year old female patient with critical ill COVID-19 was admitted in Taizhou Hospital on January 19, 2020. The patient was treated with methylprednisolone 80 mg on the 2nd day after admission. Thereafter, the dose was adjusted in a timely manner and the therapy lasted for 13 days. The peripheral lymphocyte subsets (CD3(+)T, CD4(+) T, CD8(+) T, NK cells, B cells), as well as serum levels of lymphocyte factors (IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-gamma) were dynamically monitored. RESULTS: On D1 of admission, the numbers of peripheral blood CD3(+) T, CD4(+) T, CD8(+) T, and NK cells were significantly lower than the normal range. With the improvement of the disease, the numbers of CD3(+) T, CD8(+) T and CD4 (+) T cells gradually recovered and showed a linear growth trend (linear fitting equation: Y=18.59X+109.4, P<0.05). On D2 of admission, the patient's IL-6 and IL-10 levels were significantly higher than normal values, IFN-gamma was at a normal high value, and then rapidly decreased; IL-2, IL-4, and TNF-alpha were all in the normal range. On the D6 and D7, the IL-6 and IL-10 decreased to the normal range for the first time. On the D18, the sputum virus nucleic acid test was negative for the first time, and the fecal virus nucleic acid test was still positive; on the D20 the sputum and fecal virus nucleic acid test were both negative. On D34, the patient recovered and was discharged. At the discharge the muscle strength score of the patient was 44 and the daily life ability evaluation was 90. CONCLUSIONS: In the absence of effective antiviral drugs, early use of appropriate doses of corticosteroids in critically ill patient with COVID-19 can quickly alleviate inflammatory response and improve clinical symptoms, however, it may reduce the number of T cells, and to adjust the dose in time is necessary.","Zhejiang Da Xue Xue Bao Yi Xue Ban","Zhagn, Sheng","Li, Danping","Chen, Huazhong","Zheng, Dan","Zhou, Yiping","Chen, Baoguo","Shi, Weiwu","Lin, Ronghai","32391668"],"abstract":["OBJECTIVE: To investigate the effect of corticosteroids therapy on the inflammatory response in a critically ill coronavirus disease 2019 (COVID-19) patient. METHODS: A 55-year old female patient with critical ill COVID-19 was admitted in Taizhou Hospital on January 19, 2020. The patient was treated with methylprednisolone 80 mg on the 2nd day after admission. Thereafter, the dose was adjusted in a timely manner and the therapy lasted for 13 days. The peripheral lymphocyte subsets (CD3(+)T, CD4(+) T, CD8(+) T, NK cells, B cells), as well as serum levels of lymphocyte factors (IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-gamma) were dynamically monitored. RESULTS: On D1 of admission, the numbers of peripheral blood CD3(+) T, CD4(+) T, CD8(+) T, and NK cells were significantly lower than the normal range. With the improvement of the disease, the numbers of CD3(+) T, CD8(+) T and CD4 (+) T cells gradually recovered and showed a linear growth trend (linear fitting equation: Y=18.59X+109.4, P<0.05). On D2 of admission, the patient's IL-6 and IL-10 levels were significantly higher than normal values, IFN-gamma was at a normal high value, and then rapidly decreased; IL-2, IL-4, and TNF-alpha were all in the normal range. On the D6 and D7, the IL-6 and IL-10 decreased to the normal range for the first time. On the D18, the sputum virus nucleic acid test was negative for the first time, and the fecal virus nucleic acid test was still positive; on the D20 the sputum and fecal virus nucleic acid test were both negative. On D34, the patient recovered and was discharged. At the discharge the muscle strength score of the patient was 44 and the daily life ability evaluation was 90. CONCLUSIONS: In the absence of effective antiviral drugs, early use of appropriate doses of corticosteroids in critically ill patient with COVID-19 can quickly alleviate inflammatory response and improve clinical symptoms, however, it may reduce the number of T cells, and to adjust the dose in time is necessary."],"journal":"Zhejiang Da Xue Xue Bao Yi Xue Ban","authors":["Zhagn, Sheng","Li, Danping","Chen, Huazhong","Zheng, Dan","Zhou, Yiping","Chen, Baoguo","Shi, Weiwu","Lin, Ronghai"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391668","source":"PubMed","week":"202020|May 11 - May 17","e_drugs":["Methylprednisolone"],"topics":["Case Report"],"weight":1,"_version_":1666528580184571904,"score":174.40796}]}